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ABSTRACT 
Mania and bipolar illness are the major problems in the schizophrenia treatment, zotepine, atypical antipsychotic drug used for this condition. 
The aim of present investigation was to develop mucoadhesive microemulsion of zotepine for intranasal delivery by phase titration method. 
The developed formulations were evaluated for its size, zeta, PDI and invitro release studied. The optimized formulation, containing 5% Oleic 
acid, 40% Tween 80: PEG400 (3:1) and 55% water. The globule size (53.1±0.31), zeta potential (-32.1±0.2),PDI (0.13±0.23).0.5% chitosan was 
added to the optimized formulation to prepare mucoadhesive formulation. 
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INTRODUCTION: 
Schizophrenia is a severe mental disease and chronic 
condition having world-wide occurrence of 23 million people 
approximately. [1] It is associated with three types of 
symptoms which are positive symptoms such as 
hallucinations, delusions, thought disorder, negative 
symptoms such as abnormal emotions, inability to enjoy 
pleasure and cognitive symptoms such as, inability to use 
learned skills, Inability to focus or pay attention. [2] 
Antipsychotic drugs are used for the treatment of cognitive 
symptoms and both positive and negative of schizophrenia 
[3] 
Zotepine (ZME) is a second-generation antipsychotic drug 
which appears to act as a dopamine type 1 (D1), type 2 (D2), 
serotonin (5-HT)-2A receptor antagonist and noradrenaline 
reuptake inhibitor [4] Zotepine having broad efficacy and 
improves positive and negative symptoms of Schizophrenia.  
Oral administration of drug is more convenient and well 
accepted. However, upon oral administration drug 
undergoes hepatic first pass effect. [5] Presently, ZME oral 
formulation is available in tablet which has oral 
bioavailability of 7-13%. Disadvantages of oral dosage form 
includes poor bioavailability, and slow transport along 
gastrointestinal tract. [6]  
Hence, in order to improve bioavailability of formulation 
alternative routes of administration should be preferred. In 
last three decades the intranasal drug delivery system is 
emerging delivery option for targeting to brain. It offers high 
absorption of drug, it increases the bioavailability of drug, 
reduction of drug dose in drug dose and avoidance of hepatic 
first pass effect and improved patient compliance. [8,9,10,11] 
In recent years targeting the brain through intranasal 
microemulsion based delivery systems have been studied 
extensively. [12]  
In the present study, we developed zotepine loaded 
mucoadhesive microemulsions through intranasal drug 
delivery to brain. 
MATERIALS: 
 Zotepine was received from Sun Pharmaceuticals 
limited, Hyderabad, India as gift sample, Capmul MCM was 
from Abitec corporation Ltd. Mumbai, India Cremophor RH 
40 was received as free sample from Gattefose SAS, France. 
Oleic acid, Tween 80 PEG 400, PEG600 was purchased from 
Sd fine chemicals. Chitosan, sunflower oil, castor oil from 
sigma Aldrich, Bangalore, India. 
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METHODS: 
Screening of oil 
Zotepine solubility in various oils was find out by adding an 
excess amount of drug in 5ml capacity vials containing two 
ml of the different oils, and then mixed using cyclomixer, 
then the vials were stirrer on water bath shaker at 25ºC for 
48 h. After equilibrium, vials were centrifuged at 10000 rpm 
for 10 min [13]. The supernatant was filtered through a 
membrane filter (0.45μm). The concentration of zotepine 
was determined in oils using UV spectroscopy. The study was 
carried in triplicate. 
Screening of Surfactants 
 Cremophor RH 40 and Tween 80 were screened. In water, 
surfactant solution of 2.5ml was prepared, to this add 5% 
with vertexing. If a one phase clear solution was obtained, 
the add the oil until the solution became turbid. 
Screening of Cosurfactants 
Tween 80 was combined with cosurfactant PEG400, at a 
Smix ratio of 1:1,2:1,3:1 the pseudoternary phase diagrams 
were made. Different weight ratios of oil and Smix, 
9:1,8:2,7:3,6:4,5:5,4:6,3:7,2:8 ,1:9, were taken so that 
maximum ratios were Perform to define the boundaries of 
phases precisely formed in the phase diagrams. [14,15] The 
pseudo ternary graphs are plotted by using CHEMIX 
software. 
Preparation of microemulsion containing Zotepine 
ZME formulations were prepared by water titration method 
[16] by different the ratios of oil, Surfactant, co-surfactant, 
and water; keeping the zotepine drug concentration of 
constant.  
25 mg drug was mixed with oil (Oleic acid), and to that 
surfactant mixture (Tween80:PEG400) was added and mixed 
thoroughly for 5 minutes at room temperature. The mixture 
was titrated with water drop wise until a transparent and 
stable ZME was formed. ZMMEs were prepared by adding 
0.5% w/w chitosan solution in 1% acetic acid to 
microemulsion formulation, were represented in Table 1. 
Characterization of Formulation 
Zeta potential, Globule size and Polydisperse index 
Zeta potential, Globule size, PDI and measurements were 
performed by using Zetasizer (Nano-ZS90, Malvern, 
Worcestershire, UK) by taking 1ml of formulation into 
polystyrene cuvettes for globule size and PDI and disposable 
folded capillary Cell for zeta potential at 25ºC respectively.  
Transmittance (%T) 
Transparence of microemulsion was determined by 
percentage transmittance measurement through UV 
Spectrophotometer. Percentage transmittance of samples 
was measured at 650nm with purified water taken as blank 
and triplicate were performed for each formulation [17] 
Drug content 
ZME and ZMME drug content was determined by taking 
equivalent to 25mg of zotepine and diluted using methanol. 
Samples were prepared in triplicate and the absorbance was 
measured at 278 nm using UV-Visible Spectrophotometer. 
Viscosity  
The viscosity of microemulsion was determined using 
Brookfield viscometer. Viscosity determinations were 
performed at 40 rpm at 25 ± 0.3ºC. 
pH 
The pH of microemulsion was determined by using a 
calibrated digital pH meter at room temperature by taking 5 
ml of microemulsion individually in a beaker. 
Scanning electron microscopy 
1 ml of the mucoadhesive microemulsion of zotepine 
formulation was placed on the stub. This specimen was 
observed with a scanning electron microscope, SEM 
micrographs of the microemulsion surfaces were observed. 
[18] 
Stability studies  
The optimized ZME was stored at three different 
temperature ranges for 3 months i.e., refrigerating condition 
(2– 8ºC), room temperature and elevated temperature (40 ± 
2), shelf life of the stored microemulsion system was 
evaluated by phase separation, rheological behavior, 
emulsifying time, electrical conductivity, pH, percentage 
transmittance [19] 
Statistical Analysis 
Experimental data from more than triplicate are shown as 
means ± standard deviations (SD). 
RESULTS AND DISCUSSION: 
In the development of microemulsion systems for poorly 
soluble drugs, drug loading in the formulation is very critical 
factor, which is dependent on the drug solubility in various 
components used in the formulation. Hydrophilic drugs are 
preferably solubilized in w/o microemulsions, whereas o/w 
systems seem to be a better choice for lipophilic drugs. The 
amount of the formulation should be minimized to deliver 
the therapeutic dose of the drug. Solubility of the drug in the 
oil phase is an important measure for the selection of the oil, 
it influences to maintain the drug in solubilized form in the 
microemulsion formulation. If the surfactant or cosurfactant 
is influence to drug solubilization, there could be a risk of 
precipitation. Thus, an understanding of factors that 
influencing drug loading ability while maintaining the 
capability of the system to undergo monophasic dilution 
with water and minimizing the propensity for drug 
precipitation or crystallization in diluted systems is essential 
to the development of stable and appropriately less-volume 
microemulsion systems for drug delivery applications.
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Fig. 1. Pseudo ternary phase diagram using oleic acid as oil, Tween 80 as surfactant, PEG400 as cosurfactant and water, ratio of 
S mix (Tween 80: PEG400) a) 1:1, b)2:1 c)3:1 
Oleic acid was selected as Oil Phase, Smix was Tween 80: PEG400 (3:1), water from the Pseudo ternary phase diagrams (Fig 1). 
The solubility of zotepine in different oils was determined (Table I). The solubility of zotepine was found to be highest in Oleic 
acid (130.12±1.12 mg/ml) as compared to other oils. 
Table I. Solubility of zotepine in different Oils at 25°C (mean ±SD, n=3) 
S. No Solvent Solubility (mg/ml) 
1 Capmul MCM 137.54±1.13 
2 Tween 80 264.23±1.24 
3 Cremophore R 122.3±1.54 
4 Oleic acid 430.29±0.25 
5 Castor oil 150.21±1.23 
6 Olive oil 130.12±1.12 
7 PEG 400 221.34±1.52 
8 Sunflower oil 101.12±0.38 
9 PEG600 99.43±0.23 
 
The microemulsions were selected so that all the formulations contain increasing concentrations of oil and Smix Table II.  
Table II: composition of microemulsion containing Zotepine 
Formulation Oil (%) Smix (%) Water (%) Chitosan (%) 
ZME1 5 35 60 - 
ZME 2 7.5 35 57.5 - 
ZME 3 10 35 55 - 
ZME 4 5 40 55 - 
ZME 5 7.5 40 52.5 - 
ZME 6 10 40 50 - 
ZME 7 5 45 50 - 
ZME 8 7.5 45 47.5 - 
ZME 9 10 45 45 - 
ZME 10 5 50 45 - 
ZME 11 7.5 50 42.5 - 
ZME 12 10 50 40 - 
ZME 13 5 60 35 - 
ZME 14 7.5 60 32.5 - 
ZME 15 10 60 30  
ZMME 5 40 55 0.5 
Note: Zotepine 25 mg in all formulations 
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Characterization of formulation 
Characterization of the ZME and ZMME are shown in Table 
III. The globule size was of 53.1 ± 0.31nm and 88.8±0.45nm, 
Zeta potential measurements of –32.1±0.2 and 12.5±0.47 mV 
on the globules of ZME and ZMME indicated that the system 
is physically stable and PDI of 0.13 ± 0.23 and 0.22±0.12 for 
ZME and ZMME, respectively, indicate that the ME 
approached a monophasic stable system. This 
microemulsion system can more efficiently deliver a drug 
due to the presence of a larger surface area. pH was of 6.51 
and 6.67 for the ZME and ZMME. A formulation whose pH is 
in this range may help in reduce the irritation give upon 
administration. Formulation was stable for 3 months. 
 
Table III: Characterization of Formulations. Data shown as mean ± SD (n=3) 
Formulation 
Globule Size Zeta size  
PDI 
pH Viscosity 
(nm) (mV)   (mPa-s)  
ZME1 91.1±0.18 -22.5±0.3 0.21±0.12 6.56 169 
ZME 2 67.3±1.12 -21.9±0.7 0.20±0.31 6.39 179 
ZME 3 48.1±0.14 -28.1±0.6 0.17±0.14 6.41 195 
ZME 4 53.1±0.31 -32.1±0.2 0.13±0.23 6.51 154 
ZME 5 41.3±0.26 -26.4±0.5 0.22±0.26 6.45 200 
ZME 6 49.8±0.33 -21.2±1.4 0.19±0.31 6.42 181 
ZME 7 45.4±0.56 -28.6±1.8 0.18±0.46 6.43 188 
ZME 8 125.3±0.34 -2.7±1.2 0.21±0.27 6.34 201 
ZME 9 114.4±0.67 -24.8±1.4 0.16±0.34 6.31 256 
ZME 10 126.3±0.39 -27.8±1.3 0.17±0.25 6.42 235 
ZME 11 119.4±0.52 -23.6±0.2 0.18±0.44 6.25 227 
ZME 12 105.3±0.30 -24.5±0.9 0.13±0.72 6.43 210 
ZME 13 72.6±0.44 -25.3±0.7 0.15±0.36 6.32 193 
ZME 14 82.7±0.18 -27.7±0.3 0.18±0.64 6.60 242 
ZME 15 75.8±0.23 -25.6±0.64 0.20±0.61 6.62 182 
ZMME 88.8±0.45 12.5±0.47 0.22±0.12 6.67 230 
 
Scanning electron microscopy  
Optimized formulation SEM results depicted that pure drug 
Zotepine is having rough surface, after converting in to 
microemulsion it has smooth surface, SEM micrographs of 
plain drug and Microemulsions are shown in Figure 2.
 
 
Figure 2.SEM image of a) Pure zotepine b) Optimized formulation 
 
 
CONCLUSION: 
The zotepine microemulsion formulations for intranasal 
delivery were developed by water titration method. The 
Mucoadhesive microemulsion and microemulsion 
formulation showed small globule size and good zeta 
potential and uniform distribution of globules after 3 months 
of stability studies, SEM studies shown formation of globules. 
According to this study, Microemulsion formulation is 
potential; it may be increase bioavailability of formulation 
and avoids hepatic first pass effect. Hence, the present study 
concluded that intra nasal administration of may be 
considered as replacement to oral administration
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